Ponatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings.
Am J Dermatopathol
; 45(1): 64-68, 2023 Jan 01.
Article
in English
| MEDLINE | ID: covidwho-2305584
ABSTRACT
ABSTRACT Ponatinib is a third-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Cutaneous toxicities are a commonly reported side effect of ponatinib treatment with "rash" being one of the most common. Specific subtypes are infrequently reported, but include hyperkeratotic, folliculocentric, ichthyosiform, and pityriasis rubra pilaris-like eruptions. Herein, we highlight the clinicopathologic features of 2 cases of ponatinib-induced pityriasis rubra pilaris-like eruptions. We also classify the clinical and histopathologic features of all previously reported ponatinib-associated eruptions in the literature and discuss treatment and potential diagnostic pitfalls.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pityriasis Rubra Pilaris
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Exanthema
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Am J Dermatopathol
Year:
2023
Document Type:
Article
Affiliation country:
DAD.0000000000002344
Similar
MEDLINE
...
LILACS
LIS